CytomX Therapeutics, Inc. (CTMX) tiene un P/E histórico negativo de -41.4, lo que significa que la empresa actualmente no es rentable en base a los últimos doce meses (TTM). El rendimiento de ganancias histórico es -2.42%.
Criterios demostrados por esta página:
Puntuación General SharesGrow: 69/100 con 4/7 criterios aprobados.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendimiento por Dividendo |
|---|---|---|---|---|---|
| 2016 | -6.8 | -0.11 | 5.07 | 26.47 | - |
| 2017 | -18.2 | 0.63 | 11.23 | 10.95 | - |
| 2018 | -7.4 | -0.10 | 4.81 | 10.57 | - |
| 2019 | -3.7 | -0.33 | 7.37 | 6.55 | - |
| 2020 | -4.7 | 0.07 | -38.88 | 4.42 | - |
| 2021 | -2.4 | -0.03 | -605.13 | 7.44 | - |
| 2022 | -1.1 | -0.06 | -1.23 | 1.98 | - |
| 2023 | -201.1 | 2.02 | -2.41 | 1.13 | - |
| 2024 | 2.7 | 0.00 | -190.73 | 0.63 | - |
| 2025 | -33.8 | 0.24 | 5.93 | 7.71 | 0.51% |
| Year | EPS (Diluido) | Ingresos | Ingreso Neto | Margen Neto |
|---|---|---|---|---|
| 2016 | $-1.63 | $15.04M | $-58.9M | -391.5% |
| 2017 | $-1.16 | $71.62M | $-43.1M | -60.2% |
| 2018 | $-2.03 | $59.5M | $-84.6M | -142.2% |
| 2019 | $-2.26 | $57.49M | $-102.24M | -177.8% |
| 2020 | $-0.71 | $100.36M | $-32.89M | -32.8% |
| 2021 | $-1.26 | $69.57M | $-80.65M | -115.9% |
| 2022 | $-1.48 | $53.16M | $-97.3M | -183% |
| 2023 | $-0.01 | $101.21M | $-569K | -0.6% |
| 2024 | $0.38 | $138.1M | $31.87M | 23.1% |
| 2025 | $-0.15 | $76.2M | $-17.37M | -22.8% |
| Year | EPS (Prom.) | Rango EPS | Ingresos (Prom.) | Rango de Ingresos | Analistas |
|---|---|---|---|---|---|
| 2026 | $-0.46 | $-0.62 – $-0.28 | $22.12M | $8.34M – $48.01M | 7 |
| 2027 | $-0.50 | $-0.56 – $-0.43 | $18.71M | $8.82M – $31.55M | 7 |
| 2028 | $-0.43 | $-0.69 – $-0.30 | $38.34M | $9.94M – $114.8M | 5 |
| 2029 | $-0.46 | $-1.66 – $-0.02 | $56.13M | $14.55M – $168.08M | 1 |
| 2030 | $0.04 | $0.00 – $0.15 | $196.94M | $51.05M – $589.78M | 1 |
